PT - JOURNAL ARTICLE AU - Derek Willison-Parry AU - Stephen Yang AU - Ren-Yo Forng AU - Tim Cirbo AU - Aileen Mcmeel AU - Brian Kiler AU - Christopher Phillion TI - Disinfectant Efficacy: Understanding the Expectations and How to Design Effective Studies That Include Leveraging Multi-Site Data to Drive an Efficient Program AID - 10.5731/pdajpst.2018.009662 DP - 2020 Mar 01 TA - PDA Journal of Pharmaceutical Science and Technology PG - 249--263 VI - 74 IP - 2 4099 - http://journal.pda.org/content/74/2/249.short 4100 - http://journal.pda.org/content/74/2/249.full SO - PDA J Pharm Sci Technol2020 Mar 01; 74 AB - For manufacturers of both sterile and nonsterile pharmaceuticals, there is an expectation that the manufacturing process is performed in a manner that prevents extraneous contamination so that the products are provided in a safe, integral, pure, and unadulterated form. As part of that process, cleaning and disinfection are an absolute necessity. Although cleaning and disinfection support control of microbial contamination through preventive and corrective action, specific compendia methods do not currently exist. The intent of this paper is to provide a general guidance on how to perform disinfectant efficacy validation and implementation. This includes how to make sure the concepts are understood, how to interpret facility data and utilize it to demonstrate control awareness for your facilities, and how to leverage the data to reduce redundancies in validation or verification. This paper represents the thoughts and best practices of the authoring team and their respective companies and provides an efficient way to qualify disinfectants without impacting the quality of the study. If you choose to follow the recommendations in this paper, you must ensure that the appropriate rationale is sound and the scientific data is documented. It is the belief of the authoring team that only then will this approach meet regulatory requirements.